RxDoctor Payments Data

Kevin Bartolomucci, DO

Family Medicine · Greensburg, PANPI 1255699369

Payments from drug & device makers

$685in general payments, 2019–2025

Across 13 payments — averaging $52.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$404
  • Novo Nordisk$117
  • Johnson & Johnson$81
  • Abbott$57
  • GSK$13
  • Alkermes, Inc.$13
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Speaking & faculty fees$40459%
  • Food & beverage$26839%
  • Education$132%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$685 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,071
Medicare patients
117
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$151,769
OzempicSemaglutide124$136,114
MounjaroTirzepatide84$99,968
XareltoRivaroxaban106$84,898
EliquisApixaban62$51,906
TrulicityDulaglutide26$38,354
FarxigaDapagliflozin Propanediol33$23,597
ProliaDenosumab12$20,180
TradjentaLinagliptin20$12,550
InvokanaCanagliflozin13$11,896
Spiriva RespimatTiotropium Bromide13$11,807
ShingrixVaricella-Zoster Ge/As01b/Pf51$11,243
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,064
ArexvyRsvpref3 Antigen/As01e/Pf35$10,860
Breo ElliptaFluticasone/Vilanterol26$10,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$117$136,114124 claims
Johnson & JohnsonXarelto, Invokana$81$96,794119 claims
GSKShingrix, Trelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta$13$56,780154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →